Novavax, Inc. (NVAX)
| Previous Close | 4.1200 |
| Open | 4.0700 |
| Bid | 4.0300 x 2600 |
| Ask | 4.0600 x 100 |
| Day's Range | 4.0100 - 4.1050 |
| 52 Week Range | 3.5300 - 11.3600 |
| Volume | |
| Avg. Volume | 7,566,738 |
| Market Cap | 567.509M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup
Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.
- Zacks
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
- Bloomberg
Ex-Pharma Executive and Cousin Admit to Insider Trading of Kodak
(Bloomberg) -- A former Phlow Corp. executive and his cousin admitted to insider trading on confidential information about a pandemic-related government loan to Eastman Kodak Co. Most Read from BloombergKim Jong Un Faces Annihilation in Most Korea War ScenariosApple Explores Home Robotics as Potential ‘Next Big Thing’ After Car FizzlesTSMC Facilities to Resume Production Overnight After QuakeA Million Simulations, One Verdict for US Economy: Debt Danger AheadTrump Media’s Business Doesn’t Matter
